SCHEMBL23934271

SCHEMBL23934271

Nc1cc(NC(=O)c2ccc(Cl)s2)cc2c1C(=O)NC2=O

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.68
RXFP1 Q9HBX9 3/20 0.68
NPSR1 Q6W5P4 2/20 0.68
PRKAB2 O43741 1/20 0.44
PRKAG1 P54619 1/20 0.44
PRKAA2 P54646 1/20 0.44
PRKAA1 Q13131 1/20 0.44
PRKAG3 Q9UGI9 1/20 0.44
PRKAG2 Q9UGJ0 1/20 0.44
PRKAB1 Q9Y478 1/20 0.44
NPC1 O15118 9/20 0.44
RAB9A P51151 9/20 0.44
KMT2A Q03164 8/20 0.44
MEN1 O00255 7/20 0.44
ALDH1A1 P00352 6/20 0.44
SMN1; SMN2 Q16637 4/20 0.44
NFKB1 P19838 3/20 0.44
NFKB2 Q00653 3/20 0.44
RELA Q04206 3/20 0.44
HPGD P15428 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23934287 0.82 KDM4E (0.54) KDM4ERXFP1NPSR1NPC1RAB9A
SCHEMBL23934210 0.76 KMT2A (0.51) KDM4ERXFP1KMT2AMEN1ALDH1A1
SCHEMBL23934221 0.76 CASP3 (0.60) RXFP1NPC1RAB9AKMT2AMEN1
SCHEMBL23934282 0.75 KDM4E (0.59) KDM4ERXFP1NPSR1NPC1RAB9A
SCHEMBL23934209 0.75 RXFP1 (0.47) KDM4ERXFP1NPSR1NPC1RAB9A
SCHEMBL23934277 0.74 KMT2A (0.49) RXFP1NPC1RAB9AKMT2AMEN1
SCHEMBL3379082 0.74 KDM4E (0.58) KDM4ERXFP1NPSR1NPC1RAB9A
SCHEMBL23934217 0.73 JAK2 (0.45) RXFP1PRKAA1NPC1RAB9AKMT2A
SCHEMBL23923273 0.73 RXFP1 (0.55) KDM4ERXFP1NPSR1KMT2AMEN1
SCHEMBL23934296 0.72 KMT2A (0.48) RXFP1NPC1RAB9AKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912660-B2 S6K1 protein kinase inhibitors as cancer therapeutics XAVIER UNIVERSITY OF LOUISIANA (US) 2024-02-27 US disclosed
US-20210323919-A1 S6K1 PROTEIN KINASE INHIBITORS AS CANCER THERAPEUTICS XAVIER UNIVERSITY OF LOUISIANA 2021-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210323919-A1 S6K1 PROTEIN KINASE INHIBITORS AS CANCER THERAPEUTICS RPS6KA6, RPS6KA1, RPS6KA3 KDM4E 1367/4885RXFP1 2817/4885NPSR1 2238/4885
US-11912660-B2 S6K1 protein kinase inhibitors as cancer therapeutics RPS6KA6, RPS6KA1, RPS6KA3 KDM4E 1367/4885RXFP1 2817/4885NPSR1 2238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.